Allergan's stellar Viberzi coverage bodes well for future launches: Analyst

Allergan

Some of Allergan’s key products are coming up against serious competition--meaning it’ll be up to the Dublin drugmaker’s new launches to keep the engine going strong. The way one analyst sees it, that shouldn’t be a problem.

Take Viberzi, the IBS-D drug that launched last December. The med--and a look at its formulary coverage--“demonstrates Allergan’s commercial prowess,” Bernstein analyst Ronny Gal wrote recently in a note to clients. Less than 6 months after rolling out, Viberzi is inching up on Valeant rival Xifaxan when it comes to the percentage of lives with unrestricted access, which is “not a small feat” in today’s payer environment, he noted.

And things should still be on the up-and-up, he pointed out. “We suspect that given we are still in the first year post-launch, many of the commercial formularies restricting access to Viberzi may still be negotiating with Allergan,” he wrote. Part D coverage, which takes longer to take hold, should roll around next year, too.

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

So how did Allergan get payers to flock to its IBS-D-fighter? The company does have a good relationship with payers, Gal figures; 2014 buy Forest Labs always did, and Viberzi is one of its legacy products. Gal thinks the formulary successes go further, though: “We suspect Allergan provided some attractive commercial terms and maybe some maximum spend protection for the launch of the drug,” he wrote.

There’s also the possibility payers rushed to adopt Viberzi as an alternative to Xifaxan, given that embattled Valeant--under fire for price hikes--isn’t exactly a payer favorite.

No matter how Allergan snagged all that coverage, it’s a good thing for the company that it did, Gal points out. Key Alzheimer’s drug Namenda already has generic nemeses on the market, and blockbuster eye product Restasis could soon face competition from Shire dry-eye candidate lifitegrast.

Special Report: Top 10 animated characters in pharma marketing - Xifaxan Gut Guy - Valeant

Related Articles:
Allergan continues Viberzi push with online IBS-D awareness tool
Vexing IBS-D spokescharacter 'Irritabelle' headlines Allergan's Viberzi ad push
Love it or hate it, Valeant's wobbly pink 'Gut Guy' for Xifaxan is getting noticed​
Allergan pumps up its sales rep tally amid Viberzi launch, aesthetics push
Valeant plots big DTC push for Xifaxan while rival Actavis drug waits on DEA
Ironwood steps up to challenge Valeant with Allergan's IBS med Viberzi
GI dealmaking pays off for Valeant, Actavis with same-day FDA nods in IBS

Read more on

Suggested Articles

Novartis is doing more portfolio pruning, offloading three endocrine drugs to Recordati.

Turns out, the FDA’s March rejection of Sanofi's Zynquista was just a preview of what would come for the SGLT class in Type 1 diabetes.

Indoco Remedies is not just getting the once over by the FDA but the twice-over as inspectors work through its plants and citations rain down.